Tarsus Pharmaceuticals (NASDAQ: TARS) posts corporate presentation

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. furnished a new corporate presentation under Regulation FD. The company posted the presentation on the Investor & News section of its website and attached it as Exhibit 99.1 to this report. The materials are designated as “furnished” rather than “filed,” which means they are not subject to certain liability provisions under the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings unless expressly stated.

0001819790FALSE00018197902026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 12, 2026

_______________

TARSUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

_______________

Delaware

001-39614

81-4717861

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

15440 Laguna Canyon Road, Suite 160

Irvine, CA 92618

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (949) 418-1801

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.0001 par value per share			TARS			The Nasdaq Stock Market LLC Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD.

On January 12, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) published a corporate presentation on the Investor & News section of its website, which is filed as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).

The information in this Report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference in any registration statement or other filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Tarsus Pharmaceuticals, Inc. Corporate Presentation.

104

Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARSUS PHARMACEUTICALS, INC.

Date:

January 12, 2026

/s/ Bryan Wahl

Bryan Wahl

General Counsel and Corporate Secretary

FAQ

What did Tarsus Pharmaceuticals (TARS) disclose in this 8-K?

Tarsus Pharmaceuticals disclosed that it published a corporate presentation on its Investor & News website section and furnished it as Exhibit 99.1.

Where can investors find the new Tarsus Pharmaceuticals investor presentation?

The corporate presentation is available on Tarsus Pharmaceuticals’ Investor & News section of its website and is attached as Exhibit 99.1 to this report.

Is the Tarsus Pharmaceuticals presentation considered filed or furnished with the SEC?

The report states that the information in this 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act.

Does this Tarsus Pharmaceuticals 8-K include any financial statements?

Under Item 9.01, Tarsus Pharmaceuticals lists only Exhibit 99.1 (corporate presentation) and Exhibit 104 (cover page interactive data file); no separate financial statements are listed.

What exhibits are attached to this Tarsus Pharmaceuticals 8-K?

The report includes Exhibit 99.1, Tarsus Pharmaceuticals, Inc. Corporate Presentation, and Exhibit 104, the cover page interactive data file embedded within the XBRL document.

Which SEC item does this Tarsus Pharmaceuticals 8-K primarily relate to?

The 8-K disclosure is made under Item 7.01 Regulation FD, covering the furnishing of the corporate presentation.